AG˹ٷ

STOCK TITAN

[S-8] SELLAS Life Sciences Group, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. has filed a Form S-8 to register 800,000 additional shares of common stock for issuance under its Amended and Restated 2021 Employee Stock Purchase Plan. The increase of 800,000 shares was approved by the companys stockholders on June 17, 2025. The filing incorporates prior Form S-8 information by reference and includes customary legal and accounting consents and opinions.

SELLAS Life Sciences Group, Inc. ha depositato un Form S-8 per registrare 800.000 azioni aggiuntive di azioni ordinarie da emettere ai sensi del suo Piano di Acquisto Azionario per i Dipendenti 2021, emendato e riformulato. L'aumento di 800.000 azioni è stato approvato dagli azionisti della società il 17 giugno 2025. Il deposito incorpora per riferimento le informazioni contenute nei precedenti Form S-8 e include i consensi e i pareri legali e contabili di prassi.

SELLAS Life Sciences Group, Inc. ha presentado un Form S-8 para registrar 800.000 acciones adicionales de acciones ordinarias para su emisión en virtud de su Plan de Compra de Acciones para Empleados 2021, enmendado y reformulado. El aumento de 800.000 acciones fue aprobado por los accionistas de la compañía el 17 de junio de 2025. La presentación incorpora por referencia la información de anteriores Form S-8 e incluye los consentimientos y dictámenes legales y contables habituales.

SELLAS Life Sciences Group, Inc.수정·재작성된 2021� 종업� 주식매수계획� 따라 발행하기 위해 추가� 800,000주의 보통�� 등록하기 위한 Form S-8� 제출했습니다. 800,000주의 증가� 2025� 6� 17� 회사� 주주들에 의해 승인되었습니�. 해당 제출은 이전 Form S-8� 정보� 참조� 포함하며 통상적인 법률 � 회계 동의서와 의견서를 포함합니�.

SELLAS Life Sciences Group, Inc. a déposé un Form S-8 pour enregistrer 800 000 actions supplémentaires d'actions ordinaires en vue de leur émission dans le cadre de son Plan d'achat d'actions pour salariés 2021, modifié et révisé. L'augmentation de 800 000 actions a été approuvée par les actionnaires de la société le 17 juin 2025. Le dépôt incorpore par renvoi les informations des précédents Form S-8 et inclut les consentements et avis juridiques et comptables habituels.

SELLAS Life Sciences Group, Inc. hat ein Form S-8 eingereicht, um 800.000 zusätzliche Aktien von Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten 2021 Employee Stock Purchase Plan zu registrieren. Die Erhöhung um 800.000 Aktien wurde von den Aktionären des Unternehmens am 17. Juni 2025 genehmigt. Die Einreichung bezieht frühere Form S-8-Angaben durch Verweis ein und enthält die üblichen rechtlichen und buchhalterischen Zustimmungen und Stellungnahmen.

Positive
  • Registers 800,000 additional shares of common stock for the Amended and Restated 2021 Employee Stock Purchase Plan.
  • Stockholder approval for the increase was obtained on June 17, 2025.
  • Incorporates prior Form S-8 information by reference, maintaining continuity with earlier employee-plan registrations.
Negative
  • None.

Insights

TL;DR: Routine employee-plan share increase that enables continued ESPP participation.

The registrant is adding 800,000 shares to its Amended and Restated 2021 Employee Stock Purchase Plan following stockholder approval on June 17, 2025. This filing is procedural and consistent with prior Form S-8 registrations, incorporating earlier filings by reference. There are no earnings, transaction, or governance changes disclosed here; the action simply registers additional common stock for employee issuance.

TL;DR: Governance process completed; registration documents and required consents are included.

The company filed the Form S-8 to effectuate a board-and-stockholder-approved increase in shares reserved for its ESPP and attached legal opinion and auditor consent exhibits. The filing lists Exhibit 99.1 as the Amended and Restated 2021 Employee Stock Purchase Plan and includes the power of attorney and filing fee table. No material adverse disclosures or management changes are present in this document.

SELLAS Life Sciences Group, Inc. ha depositato un Form S-8 per registrare 800.000 azioni aggiuntive di azioni ordinarie da emettere ai sensi del suo Piano di Acquisto Azionario per i Dipendenti 2021, emendato e riformulato. L'aumento di 800.000 azioni è stato approvato dagli azionisti della società il 17 giugno 2025. Il deposito incorpora per riferimento le informazioni contenute nei precedenti Form S-8 e include i consensi e i pareri legali e contabili di prassi.

SELLAS Life Sciences Group, Inc. ha presentado un Form S-8 para registrar 800.000 acciones adicionales de acciones ordinarias para su emisión en virtud de su Plan de Compra de Acciones para Empleados 2021, enmendado y reformulado. El aumento de 800.000 acciones fue aprobado por los accionistas de la compañía el 17 de junio de 2025. La presentación incorpora por referencia la información de anteriores Form S-8 e incluye los consentimientos y dictámenes legales y contables habituales.

SELLAS Life Sciences Group, Inc.수정·재작성된 2021� 종업� 주식매수계획� 따라 발행하기 위해 추가� 800,000주의 보통�� 등록하기 위한 Form S-8� 제출했습니다. 800,000주의 증가� 2025� 6� 17� 회사� 주주들에 의해 승인되었습니�. 해당 제출은 이전 Form S-8� 정보� 참조� 포함하며 통상적인 법률 � 회계 동의서와 의견서를 포함합니�.

SELLAS Life Sciences Group, Inc. a déposé un Form S-8 pour enregistrer 800 000 actions supplémentaires d'actions ordinaires en vue de leur émission dans le cadre de son Plan d'achat d'actions pour salariés 2021, modifié et révisé. L'augmentation de 800 000 actions a été approuvée par les actionnaires de la société le 17 juin 2025. Le dépôt incorpore par renvoi les informations des précédents Form S-8 et inclut les consentements et avis juridiques et comptables habituels.

SELLAS Life Sciences Group, Inc. hat ein Form S-8 eingereicht, um 800.000 zusätzliche Aktien von Stammaktien zur Ausgabe im Rahmen seines geänderten und neu gefassten 2021 Employee Stock Purchase Plan zu registrieren. Die Erhöhung um 800.000 Aktien wurde von den Aktionären des Unternehmens am 17. Juni 2025 genehmigt. Die Einreichung bezieht frühere Form S-8-Angaben durch Verweis ein und enthält die üblichen rechtlichen und buchhalterischen Zustimmungen und Stellungnahmen.

As filed with the Securities and Exchange Commission on August 12, 2025

 

Registration No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

 

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

_______________

 

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)

_______________

 

Delaware

20-8099512

(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)

 

7 Times Square, Suite 2503
  New York, NY 10036

 

(Address of Principal Executive Offices) (Zip Code)

_______________

 

SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan

(Full title of the plan)

_______________

 

Angelos M. Stergiou, M.D., ScD h.c.

President and Chief Executive Officer

SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, NY 10036

Telephone: (640) 200-5278

(Name and address of agent for service)

(Telephone number, including area code, of agent for service)

 

Copies to:

 

Joel I. Papernik, Esq.

Daniel A. Bagliebter, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

919 Third Avenue, New York, NY 10022

(212) 935-3000

_______________

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

 

 

 

 

EXPLANATORY NOTE

 

SELLAS Life Sciences Group, Inc. (the “Registrant”) has prepared this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register 800,000 additional shares of common stock, par value $0.0001 per share (“Common Stock”), for issuance under the SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (the “Plan”), representing an increase of 800,000 shares reserved under the Plan, as approved by the Registrant’s stockholders at the Registrant’s annual meeting of stockholders on June 17, 2025.

 

This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed on Form S-8 (SEC File Nos. 333-237168, 333-258799, 333-264899, 333-270608, and 333-276615) of the Registrant is effective. The information contained in the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission on March 13, 2020 (File No. 333-237168), August 13, 2021 (File No. 333-258799), May 12, 2022 (File No. 333-264899), March 16, 2023 (File No. 333-270608), and January 19, 2024 (333-276615) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

Exhibit
Number
  Exhibit Description   Filed
Herewith
  Incorporated by
Reference herein from
Form or Schedule
  Filing Date   SEC File/
Reg.
Number
                     
3.1   Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017       Form 10-K
(Exhibit 3.1)
  April 13, 2018   001-33958
                     
3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation       Form 10-K
(Exhibit 3.3)
  March 23, 2021   001-33958
                     
3.3   Amended and Restated By-Laws of the Registrant       Form 8-K
(Exhibit 3.3)
  January 5, 2018   001-33958
                     
5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.   X            
                     
23.1   Consent of Baker Tilly US, LLP, independent registered public accounting firm.   X            
                     
23.2   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)   X            
                     
24.1   Power of Attorney (included on the signature page hereof)   X            
                     
99.1+   SELLAS Life Sciences Group, Inc. Amended and Restated 2021 Employee Stock Purchase Plan       Form 10-Q
(Exhibit 10.1)
  August 12, 2025   001-33958
                     
107   Filing Fee Table   X            

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on August 12, 2025.

 

  SELLAS LIFE SCIENCES GROUP, INC.
   
  By: /s/ Angelos M. Stergiou     
  Angelos M. Stergiou, M.D., ScD h.c.
  President and Chief Executive Officer

 

Each person whose signature appears below constitutes and appoints each of Angelos M. Stergiou and John T. Burns, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

Title

Date

/s/ Angelos M. Stergiou

President, Chief Executive Officer and Director (Principal Executive Officer) August 12, 2025
Angelos M. Stergiou, M.D., ScD h.c.
     

/s/ John T. Burns

Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) August 12, 2025
John T. Burns    
     

/s/ John Varian

Chair of the Board of Directors August 12, 2025
John Varian    
     

/s/ David Scheinberg

Director August 12, 2025
David Scheinberg, M.D., PhD.    
     

/s/ Robert Van Nostrand

Director August 12, 2025
Robert Van Nostrand    
     

/s/ Jane Wasman

Director August 12, 2025
Jane Wasman    
     
     

/s/ Katherine Kalin

Director August 12, 2025
Katherine Kalin    

 

 

 

 

FAQ

What does SELLAS (SLS) register on this Form S-8?

The company registers 800,000 additional shares of common stock for issuance under its Amended and Restated 2021 Employee Stock Purchase Plan.

When were the additional shares approved for the ESPP?

The increase of 800,000 shares was approved by SELLAS stockholders on June 17, 2025.

Does the filing include supporting exhibits and consents?

Yes. The filing includes a legal opinion (Exhibit 5.1), the independent auditor consent (Exhibit 23.1), the amended ESPP as Exhibit 99.1, a power of attorney and the filing fee table.

Is this Form S-8 related to prior registrations?

Yes. The registration statement states it registers additional securities of the same class as prior Form S-8 filings and incorporates those prior filings by reference.

Who signed the registration statement for SELLAS?

The document is signed on behalf of the company by Angelos M. Stergiou, President and Chief Executive Officer, with other executive and board signatures included.
Sellas Life Sciences Group Inc

NASDAQ:SLS

SLS Rankings

SLS Latest News

SLS Latest SEC Filings

SLS Stock Data

153.66M
99.44M
0.34%
14.85%
27.8%
Biotechnology
Pharmaceutical Preparations
United States
NEW YORK